New oligomer shows promising anti-SARS-CoV-2 properties

NewsGuard 100/100 Score

Coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. With few treatments, a rapid transmission rate, and high mortality amongst at-risk groups such as the elderly, the disease quickly grew into a pandemic, spreading to nearly every country by the end of 2020.

The pandemic has resulted in more than 4.9 million deaths, and many governments have been forced to enact harsh restrictions in an effort to prevent more spread, causing global economic crises.

While mass vaccination schemes appear to be beginning to help control the disease, there are still relatively few treatments available. While there was widespread media attention around hydroxychloroquine and ivermectin, neither showed any effectiveness in respected clinical trials.

Monoclonal antibody treatments have shown some small improvements in patients, but may contribute to immune cell infection. Recent studies have indicated certain statins may be effective in reducing mortality, but this has not been confirmed.

Scientists from the University Of New Mexico have recently identified a new cationic oligomer that may help inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

A preprint version of the group’s study is available on the bioRxiv* server, while the article undergoes peer review.

The researchers identified that oligomers of poly-phenylene ethynylene act as powerful antiviral agents. They showed that non-enveloped viruses that attack Escherichia coli could display antiviral activity under both light-activation and dark treatment with several different cationic oligomers and polyelectrodes. However, when scientists developed antimicrobial reagents based on these principles, they discovered that they only showed effectivity against SARS-CoV-2 when activated by ultraviolet or visible light.

The materials they developed included a set of cationic polyphenylene-ethynylenes and polythiophenes and smaller cationic and anionic oligomers. They assumed the lack of ability to inactivate SARS-CoV-2 under dark treatment was due to the viral envelope of SARS-CoV-2.

Top: functional components of end-only functionalized oligomers. Structures of 1 and 2 used in this study are shown below.
Top: functional components of end-only functionalized oligomers. Structures of 1 and 2 used in this study are shown below.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

While the materials cannot penetrate this envelope, they still engage in a ground state docking process that enables the formation of a singlet of oxygen from the excited tripler of the oligomer. This singlet oxygen may be able to penetrate further into the virus.

The most straightforward effective material was an end-only OPE (EO-OPE-1), where the chromophore and charged groups could be easily tuned. After creating two OPEs with different charged end groups, they found that the second was not soluble in water, making it difficult to use and test.

The other OPE, Oligomer 1, was initially tested against Escherichia coli, before advancing to SARS-CoV-2. Initially, the log reduction in Escherichia coli concentration (log kill) was examined with oligomer 1 at concentrations of 10ug/mL, 1ug/mL, and 0.1ug/mL with 5, 10, and 30 minutes of irradiation time. Control experiments showed no killing of Escherichia coli in the control dark or with the white lamp alone. At 10ug/mL, oligomer 1 proved effective at killing Escherichia coli no matter the irradiation time, while at 1ug/mL, irradiation of 10 minutes or over was required. At 0.1ug/mL, no killing was observed even at 30 minutes of irradiation.

Dark conditions with any concentration also showed very little killing. However, when these tests were repeated on paper and glass fiber filters, a final concentration of 10ug/mL again showed significant inactivation – proving the molecule could prove effective when adsorbed to a support structure.

Further experiments using SARS-CoV-2 rather than Escherichia coli showed again significant log killing under light conditions, with 3 logs, or 99.9% of the virus inactivated, after 5 minutes exposure at 10ug/mL.

Cell counting of serial dilutions of E. coli. Under irradiation of 10 μg/mL of compound 1 with visible light and in dark (above, left) and graphical representations of log kills in dark and light. There was no killing on irradiation (Control Light) and dark control (Control Dark) samples.
Cell counting of serial dilutions of E. coli. Under irradiation of 10 μg/mL of compound 1 with visible light and in dark (above, left) and graphical representations of log kills in dark and light. There was no killing on irradiation (Control Light) and dark control (Control Dark) samples.

The successful killing of viruses and bacteria while adsorbed to filters should allow the material to be used in air or water decontamination systems.

The authors highlight the importance of their discoveries in helping to eliminate SARS-CoV-2 on surfaces, hastening the end of the pandemic.

While the toxicity of the material and the need for visible light irradiation prevents the use of the oligomer as a treatment, the ability of the oligomer to kill both SARS-CoV-2 and Escherichia coli while mounted on a support suggests it would be very useful in filtration devices, or on wipes to help ensure sterility in commonly touched areas.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 1 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Sam Hancock

Written by

Sam Hancock

Sam completed his MSci in Genetics at the University of Nottingham in 2019, fuelled initially by an interest in genetic ageing. As part of his degree, he also investigated the role of rnh genes in originless replication in archaea.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hancock, Sam. (2023, May 01). New oligomer shows promising anti-SARS-CoV-2 properties. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20211020/New-oligomer-shows-promising-anti-SARS-CoV-2-properties.aspx.

  • MLA

    Hancock, Sam. "New oligomer shows promising anti-SARS-CoV-2 properties". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20211020/New-oligomer-shows-promising-anti-SARS-CoV-2-properties.aspx>.

  • Chicago

    Hancock, Sam. "New oligomer shows promising anti-SARS-CoV-2 properties". News-Medical. https://www.news-medical.net/news/20211020/New-oligomer-shows-promising-anti-SARS-CoV-2-properties.aspx. (accessed April 25, 2024).

  • Harvard

    Hancock, Sam. 2023. New oligomer shows promising anti-SARS-CoV-2 properties. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20211020/New-oligomer-shows-promising-anti-SARS-CoV-2-properties.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 linked to higher dementia risk in older adults, study finds